Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of ... HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio ...
News
- Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 ...
- Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of ...
... drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that .... NERLYNX is a registered trademark of Puma Biotechnology, Inc.
- Puma Biotech (PBYI) Announces Results from Phase II SUMMIT Trial of Neratinib for ERBB2 ...
Puma Biotech (PBYI) Announces Results from Phase II SUMMIT Trial of ... Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, ... at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently ...
- Puma Biotech (PBYI) Highlights Updated Data from Patient Reported Outcomes in Phase II ...
Puma Biotechnology, Inc. (NASDAQ: PBYI) is presenting updated results from a Phase II clinical trial of Puma's drug neratinib at the 2018 San Antonio ...
- Recon: HHS Defends Drug Pricing Proposal; Mallinckrodt to Spin Off Specialty Generics Business
Pharmaceuticals & Biotechnology ... Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium (Press); Puma Biotechnology Presents ...